Is CRVS or CTOR more undervalued in 2026?

CirclFi compares Corvus Pharmaceuticals, Inc. (CRVS) and Citius Oncology, Inc. (CTOR) using 13 institutional-grade valuation models. CRVS has a Quality of Company score of 4.6/10 while CTOR scores 3.4/10.

Which is a better buy — CRVS or CTOR?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CRVS and CTOR valuations compare?

CRVS at $12.41 and CTOR at $0.80 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CRVS vs CTOR Valuation Comparison 2026 — Intrinsic Value Analysis

CRVS

Pharmaceutical Preparations

Corvus Pharmaceuticals, Inc.

Quality

4.6

out of 10

Value Trap

SAFE

Price

$12.41

Last close

Models

7/13

Active

CTOR

Pharmaceutical Preparations

Citius Oncology, Inc.

Quality

3.4

out of 10

Value Trap

SAFE

Price

$0.80

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	CRVS Fair Value	CRVS Upside	CTOR Fair Value	CTOR Upside
Bayesian DCF	Intrinsic	$3.63	-70.7%	$0.24	-70.0%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.51	-96.7%	$0.08	-91.8%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CRVS vs CTOR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CRVS vs CTOR — Which Stock Is More Undervalued?

CRVS scores higher with a 4.6/10 quality rating vs CTOR's 3.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Corvus Pharmaceuticals, Inc. (CRVS) and Citius Oncology, Inc. (CTOR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CRVS currently trades at $12.41 with a QOC of 4.6/10, while CTOR trades at $0.80 with a QOC of 3.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).